Resistance to chemotherapy in acute leukemia

Current Opinion in Oncology

Volumn 10, Issue 1, 1998, Pages 31-35

  Löwenberg, Bob ^a   Sonneveld, Pieter ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; QUININE; TIAZOFURIN; VALSPODAR; VINBLASTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; HUMAN; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; NAUSEA; NEUTROPENIA; PATIENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VOMITING;

EID: 0031975817     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199801000-00006     Document Type: Review

References (39)

1. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, et al.: A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996, 87:1710-1717.
2. Weick JK, Kopecky J, Appelbaum R, Head DR, Kingsburry LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, et al.: A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a southwest oncology group study. Blood 1996, 88:2841-2851.
3. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E: Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994, 331:896.
4. Tricot G, Weber G: Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5 phosphate dehydrogenase activity. Anticancer Res 1996, 16:3341-3347.
5. Hanna M, Gros P: Cloning and structure: function analysis of the mouse mdr1 gene family. In Multidrug Resistance in Cancer Cells. Edited by Gupta S, Tsuruo T. Chichester: John Wiley & Sons, 1996:5-28.
6. Germann UA: Molecular analysis of P-glycoprotein. Eur J Cancer 1996, 32A:927-944.
7. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordauw AC, van Tellingen O, Zijlmans JM, et al.: Normal viability and altered pharmacokinetics in mice lacking the mdr1 type (drug-transporting) p-glycoproteln. Proc Natl Acad Sci USA 1997, 94:4028-4033.
8. Loe DW, Deeley RG, Cole SPW: Biology of the multidrug resistance in tumour cells. Eur J Cancer 1996, 32A:945-957.
9. Nooter K, Stoter G: Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract 1996, 192:766-780.
10. Izquierdo MA, Scheffer GL, Flens MJ, Schroeijers AB, van der Valk P, Scheper RJ: Major vault protein LRP-related multidrug resistance. Eur J Cancer 1996, 32A:979-984.
11. Izquierdo MA, Scheffer GL, Flens MJ, Shoemaker RH, Rome LH, Scheper RJ: Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs. Cytotechnology 1996, 19:191-197.
12. Nitise U, Beck WT: Anti-topoisomerase drug action and resistance. Eur J Cancer 1996, 32A:958-966.
13. Sato H, Gottesmann MM, Goldstein LJ, et al.: Expression of the multidrug resistance gene in myeloid leukemias. Leukemia Res 1990, 14:11-22.
14. Pirker R, Wallner J, Geissler K, et al.: MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991, 83:708-712.
15. Marie JP, Zittoun R, Sikic BI: Multidrug resistance (MDR1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991, 78:586-592.
16. Zhou DC, Marie JP, Suberville AM, Zittoun R: Relevance of MDR1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 1992, 6:879-855.
17. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D: Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992, 79:473-476.
18. Te Boekhorst PAW, De Leeuw K, Schoester M, Wittebol S, Nooter K, Hagemeijer A, Lowenberg B, Sonneveld P: Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ leukemia cells. Blood 1993, 82:3157-3162.
19. Ino T, Miyazaki H, Isogai M, Nomura T, Tsuzuki M, Tsuruo I, Ezaki K, Hirano M: Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome. Leukemia 1994, 8:1492-1497.
20. Lamy T, Goasguen JE, Mordelet E, Grulois I, Dauriac C, Drenou B, Chaperon J, Fauchet R, lePrise PY: P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML). Leukemia 1994, 8:1879-1883.
21. Leith CP, Kopecky KJ, Chen IM, Godwin JE, Appelbaum FR, Head DR, Willman CL: Correlation of functional efflux and multidrug resistance (MDR1) expression in acute myeloid leukemia (AML) in the elderly: MDR1 and secondary AML status are independent predictors of complete remission (CR) [abstract]. Blood 1994, 84:3771.
22. Paietta E, Andersen J, Racevskis J: Multidrug resistance gene (MDR1) transcript or CD34 antigen expression levels do not predict for complete remissions in de novo adult acute myeloid leukemia (AML): an Eastern cooperative oncology group study. Blood 1994, 84:3771.
23. te Boekhorst PA, Löwenberg B, Van Kapel J, Nooter K, Sonneveld P: Multidrug resistant cells with high proliferate capacity determine response to therapy in acute myelold leukemia. Leukemia 1995, 9:1025-1031.
24. Guerci A, Merlin HL, Missouri N, Feldmann L, Marchal S, Witz F, Rose C, Guerci O: Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorublcin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 1995, 85:2147-2153.
25. Pogliani EM, Belotti D, Rivolta GF, Maffe PF, Corneo G: Anthracycllne drugs and MDR expression in human leukemia. Cytotechnology 1996, 19:229-235.
26. Totomeo M, Gancitano RA, Musso M, Porretto F, Perricone R, Abbadessa V, Cajozzo A: Comparative activity of idarubicin and idarubicinol in combination with cydosporine A in multidrug-resistant leukemia cells. Cancer Chemother Pharmacol 1996, 39:157-161.
27. Hunault M, Zhou D, Delmer A, Ramond S, Viguie F, Cadiou M, Perrot JY, Levy V, Rio B, Cymbalista F, et al.: Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment. Ann Hematol 1997, 74:65-71.
28. Michieli M, Damiani D, Ermacora A, Raspadori D, Michelutti A, Grimaz S, Fanin R, Russo D, Lauria F, Masolini P, et al.: P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells. Br J Haematol 1997, 96:356-365.
29. Tafuri A, Sommaggio A, Burba L, Albergoni MP, Petrucci MT, Mascolo MG, Testi AM, Basso G: Prognostic value of rhodamine-efflux and MDR-1/P-170 expression in childhood acute leukemia. Leuk Res 1995, 19:927-931.
30. List AF: Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 1996, 10:937-942.
31. List AF: The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 1996, 10(suppl 1):S36-S38.
32. Broxterman HJ, Sonneveld P, Feller N, Ossenkoppele GJ, Währer DRC, Eekman CA, Schoester M, Lankelma J, Pinedo HM, Löwenberg B, et al.: Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood 1996, 87:4809-4816.
33. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, et al.: Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996, 56:3010-3020.
34. Hegewisch-Becker S: MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Leukemia 1996, 10(suppl 3):S32-S38.
35. Sonneveld P: Multidrug resistance in acute leukemia. Baillière Clin Haematol 1995, 8:831-844.
36. Solary E, Witz B, Caillot D, Moreau P, Desablens B, Cahn JY, Sadoun A, Pignon B, Berthou C, Maloisel F, et al.: Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 1996, 88:1198-1205.
37. Schiffer CA: Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 1996, 88:3675-3685.
38. Terpstra WE, Löwenberg B: Application of myeloid growth factors in the treatment of acute myeloid leukemia. Leukemia 1997, 11:315-327.
39. Rowe JM, Liesveld JL: Hematopoietic growth factors in acute leukemia. Leukemia 1997, 11:328-341.